PredictImmune
Developer of pioneering prognostic tools
Company bio
Founded in May 2017 and based at the Babraham Research Campus in Cambridge, PredictImmune develops pioneering tools for guiding treatment options in immune-mediated inflammatory diseases like Crohn’s and ulcerative colitis (IBD).
Based on ten years of research at Cambridge University, PredictImmune’s test kits help both clinicians and patients to understand, at the point of diagnosis, the likely course of disease and opens the possibility of better treatment choices from the outset.
Company
information
BGF office
London
BGF team
Tim Rea
Nathan Heath
Invested since
July 2019
Total BGF investment
£4m